Author:
Leng Xiaomei,Leszczyński Piotr,Jeka Slawomir,Liu Shengyun,Liu Huaxiang,Miakisz Malgorzata,Gu Jieruo,Kilasonia Lali,Stanislavchuk Mykola,Yang Xiaolei,Zhou Yinbo,Dong Qingfeng,Mitroiu Marian,Addison Janet,Rezk Mourad F.,Zeng Xiaofeng
Abstract
Abstract
Background
Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) of the phase 3 study. Here we present results for TP2 (study weeks 24–48).
Methods
In this phase 3, multicenter, multiregional, double-blind, active-controlled, equivalence study, participants with active RA despite methotrexate were randomized (1:1:2) to intravenous administration of 8 mg/kg TCZ every 4 weeks to week 48 (TCZ group), or TCZ to week 24 followed by BAT1806/BIIB800 to week 48 (TCZ to BAT1806/BIIB800 group), or BAT1806/BIIB800 to week 48 (BAT1806/BIIB800 group). Efficacy in TP2 was evaluated using American College of Rheumatology (ACR) response criteria (ACR20/50/70) and change from baseline in Disease Activity Score on 28 joints (DAS28). Pharmacokinetics (trough levels), safety, and immunogenicity were also evaluated.
Results
Of 621 randomized participants, 577 (92.9%) completed TP1 and entered TP2 (TCZ: N = 145 [93.5%]; TCZ to BAT1806/BIIB800: N = 142 [92.2%]; BAT1806/BIIB800: N = 290 [92.9%]). Proportions of ACR20 responders were similar between treatment groups throughout TP2 (87.8%, 90.3%, and 90.4%, respectively, at week 48), as were proportions of ACR50 and ACR70 responders, and reduction in DAS28. Drug trough levels and antidrug antibody incidences were comparable between the treatment groups. Adverse events were balanced across the treatment groups and no fatal events were reported.
Conclusion
In TP2, efficacy, safety, immunogenicity, and pharmacokinetic profiles were comparable between the TCZ, TCZ to BAT1806/BIIB800, and BAT1806/BIIB800 groups.
Trial registration
NCT03830203 and EudraCT 2018-002202-31.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Center for Drug Evaluation of the National Medical Products Administration. Technical guidelines for the development and evaluation of biosimilar drugs (in Chinese). [Internet]. 2015. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=f044cdf4b7d7286aa12ffb85fc81a74c. Accessed January 12, 2023.
2. European Medicines Agency. Guideline on similar biological medicinal products [Internet]. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed August 16, 2022.
3. US Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations [Internet]. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality. Accessed August 16, 2022.
4. Zhang H, Wang H, Wei H, Chen H, Liu J, Li C, et al. A phase I clinical study comparing the tolerance, immunogenicity, and pharmacokinetics of proposed biosimilar BAT1806 and reference tocilizumab in healthy Chinese men. Front Pharmacol. 2020;11:609522.
5. Leng X, Leszczynski P, Jeka S, Liu SY, Liu H, Miakisz M, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Lancet Rheumatol. 2024;6(1):e40–50.